Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
503 Leser
Artikel bewerten:
(1)

NMS Consulting, Inc.: NMS Consulting Selected as Strategic Advisor to Cerebain Biotech Corp. for Acquisition Project

Finanznachrichten News

BEVERLY HILLS, CA / ACCESSWIRE / October 6, 2020 / NMS Consulting, Inc. ("NMS") is pleased to announce that it has been selected as strategic advisor by Cerebain Biotech Cop. (OTCPINK:CBBT) ("Cerebain") for its planned acquisition of PKG, Inc. ("PKG").

NMS Consulting Logo

As part of the initial scope of services, NMS shall provide management consulting services related to the formal due diligence of the PKG operations and financials in addition to analysis related to revenue and cost synergies/savings, human capital and performance optimization, tax advisory, and mitigation strategy, risk management strategy, transaction and financing structuring to ensure optimal benefits to Cerebain and its shareholders. Additional services shall include post-merger integration, revenue growth strategies, market entry and expansion, digital transformation, cyber-security, and data privacy.

Trevor M. Saliba, Managing Partner and Global Head of Private Equity, M&A, and Strategy of NMS said, "We are very excited to continue working with Cerebain on this mandate. Having them as our client since 2018, we have had the privilege of working with them on various initiatives in preparation of their growth strategy. The acquisition of PKG begins the implementation of their long-term business plan."

Irvine, California based Cerebain recently announced that it had executed a letter of intent to acquire all assets of PKG, an Idaho based leading contract manufacturing firm specializing in contract design, development, and manufacturing of system-level devices within the medical, aerospace, government, and industrial products sectors.

Eric Clemons, CEO of Cerebain said, "NMS Consulting has been invaluable in advising us on constructing our long-term corporate growth strategy. As we look to complete the PKG acquisition milestone, we are looking forward to continue working with the NMS Consulting team and their providing strategic counsel related to the integration of the PKG operations into Cerebain and moving to the next steps of growing Cerebain in accordance with our internal plan to maximize shareholder value."

To learn more about Cerebain, please visit www.cerebain.com or connect with them on Twitter and Facebook.

About NMS Consulting

NMS Consulting, Inc. is a global management consulting firm providing strategic counsel to private and public organizations and the individuals who lead them. The firm operates through four business segments; Management Consulting, Corporate Advisory, Strategic Communications, and Tax Advisory. The Management Consulting group engages with clients to provide such services as Change Management, Turnaround and Restructuring, Transformation, Mergers and Acquisitions, and Post-Merger Integration. The Corporate Advisory group engages with clients to provide services, which include Corporate Governance, Strategy, Marketing and Sales, Risk Management, Technology Advisory, and Structured and Specialty Finance. The Strategic Communications group advises clients on Branding and Communications, Digital Media, and Capital Markets campaigns. The Tax Advisory group engages with clients to provide counsel on General Tax, M&A Tax, State, Local, and Property Tax advisory. For more information, please visit, www.nmsconsulting.com

Media Contact:

USA
Lili Swanson
+1.310.855.0020
info@nmsconsulting.com

EUROPE
Sophia Binder
+44 20 3895 3540
sbinder@nmsconsulting.com

SOURCE: NMS Capital Group, LLC



View source version on accesswire.com:
https://www.accesswire.com/609333/NMS-Consulting-Selected-as-Strategic-Advisor-to-Cerebain-Biotech-Corp-for-Acquisition-Project

© 2020 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.